Jim Simons Gilead Sciences, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 5,451,143 shares of GILD stock, worth $596 Million. This represents 0.98% of its overall portfolio holdings.

Number of Shares

5,451,143

Previous 5,329,743 2.28%

Holding current value

$596 Million

Previous $492 Million 24.07%

% of portfolio

0.98%

Previous 0.78%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$89.14 - $117.41 $10.8 Million - $14.3 Million	121,400 Added 2.28%	5,451,143 $611 Million
Q4 2024 Feb 13, 2025	BUY	$83.95 - $97.9 $95.8 Million - $112 Million	1,141,219 Added 27.25%	5,329,743 $492 Million
Q3 2024 Nov 13, 2024	SELL	$66.59 - $83.99 $57.9 Million - $73 Million	-869,074 Reduced 17.18%	4,188,524 $351 Million
Q2 2024 Aug 09, 2024	BUY	$63.15 - $72.88 $46.7 Million - $53.9 Million	739,948 Added 17.14%	5,057,598 $347 Million
Q1 2024 May 13, 2024	SELL	$71.58 - $87.29 $90.1 Million - $110 Million	-1,258,200 Reduced 22.57%	4,317,650 $316 Million
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $63.6 Million - $72.1 Million	-867,534 Reduced 13.46%	5,575,850 $452 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $98.9 Million - $108 Million	-1,338,032 Reduced 17.2%	6,443,384 $483 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $213 Million - $243 Million	-2,802,800 Reduced 26.48%	7,781,416 $600 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $107 Million - $122 Million	1,381,648 Added 15.01%	10,584,216 $878 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $51.1 Million - $73.4 Million	-820,000 Reduced 8.18%	9,202,568 $790 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $202 Million - $230 Million	-3,387,048 Reduced 25.26%	10,022,568 $618 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $120 Million - $135 Million	-2,082,500 Reduced 13.44%	13,409,616 $829 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $371 Million - $465 Million	6,410,047 Added 70.58%	15,492,116 $921 Million
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $232 Million - $264 Million	3,581,114 Added 65.1%	9,082,069 $659 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $30.7 Million - $33.1 Million	453,600 Added 8.99%	5,500,955 $384 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $96.1 Million - $105 Million	-1,513,648 Reduced 23.07%	5,047,355 $348 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $11.2 Million - $12.8 Million	186,241 Added 2.92%	6,561,003 $424 Million
Q4 2020 Feb 10, 2021	SELL	$56.65 - $64.55 $72.3 Million - $82.4 Million	-1,277,117 Reduced 16.69%	6,374,762 $371 Million
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $77.6 Million - $97.6 Million	-1,249,368 Reduced 14.04%	7,651,879 $484 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $263 Million - $305 Million	-3,629,962 Reduced 28.97%	8,901,247 $685 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $278 Million - $356 Million	-4,431,735 Reduced 26.13%	12,531,209 $937 Million
Q4 2019 Feb 13, 2020	BUY	$61.62 - $67.78 $137 Million - $151 Million	2,228,686 Added 15.13%	16,962,944 $1.1 Billion
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $125 Million - $138 Million	1,994,010 Added 15.65%	14,734,258 $934 Million
Q2 2019 Aug 12, 2019	BUY	$61.87 - $69.38 $286 Million - $321 Million	4,620,000 Added 56.89%	12,740,248 $861 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $171 Million - $191 Million	2,730,700 Added 50.67%	8,120,248 $528 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $326 Million - $426 Million	5,389,548 New	5,389,548 $337 Million

Others Institutions Holding GILD

# of Institutions

2,287

Shares Held

997M

Call Options Held

9.62M

Put Options Held

10M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $137B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account